BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 15340197)

  • 21. Novel cyclic compounds as potent phosphodiesterase 4 inhibitors.
    He W; Huang FC; Hanney B; Souness J; Miller B; Liang G; Mason J; Djuric S
    J Med Chem; 1998 Oct; 41(22):4216-23. PubMed ID: 9784096
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor.
    Macdonald D; Mastracchio A; Perrier H; Dubé D; Gallant M; Lacombe P; Deschênes D; Roy B; Scheigetz J; Bateman K; Li C; Trimble LA; Day S; Chauret N; Nicoll-Griffith DA; Silva JM; Huang Z; Laliberté F; Liu S; Ethier D; Pon D; Muise E; Boulet L; Chan CC; Styhler A; Charleson S; Mancini J; Masson P; Claveau D; Nicholson D; Turner M; Young RN; Girard Y
    Bioorg Med Chem Lett; 2005 Dec; 15(23):5241-6. PubMed ID: 16168647
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improvement of therapeutic index of phosphodiesterase type IV inhibitors as anti-Asthmatics.
    Kim E; Chun HO; Jung SH; Kim JH; Lee JM; Suh BC; Xiang MX; Rhee CK
    Bioorg Med Chem Lett; 2003 Jul; 13(14):2355-8. PubMed ID: 12824033
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and biological activities of 1-pyridylisoquinoline and 1-pyridyldihydroisoquinoline derivatives as PDE4 inhibitors.
    Ukita T; Sugahara M; Terakawa Y; Kuroda T; Wada K; Nakata A; Kikkawa H; Ikezawa K; Naito K
    Bioorg Med Chem Lett; 2003 Jul; 13(14):2347-50. PubMed ID: 12824031
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Substituted 4-(2,2-diphenylethyl)pyridine-N-oxides as phosphodiesterase-4 inhibitors: SAR study directed toward the improvement of pharmacokinetic parameters.
    Frenette R; Blouin M; Brideau C; Chauret N; Ducharme Y; Friesen RW; Hamel P; Jones TR; Laliberté F; Li C; Masson P; McAuliffe M; Girard Y
    Bioorg Med Chem Lett; 2002 Oct; 12(20):3009-13. PubMed ID: 12270195
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor.
    Bundschuh DS; Eltze M; Barsig J; Wollin L; Hatzelmann A; Beume R
    J Pharmacol Exp Ther; 2001 Apr; 297(1):280-90. PubMed ID: 11259555
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quaternary substituted PDE4 inhibitors I: the synthesis and in vitro evaluation of a novel series of oxindoles.
    Hulme C; Poli GB; Huang FC; Souness JE; Djuric SW
    Bioorg Med Chem Lett; 1998 Jan; 8(2):175-8. PubMed ID: 9871649
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and biological studies of catechol ether type derivatives as potential phosphodiesterase (PDE) IV inhibitors.
    Rhee CK; Kim JH; Suh BC; Xiang MX; Youn YS; Bang WY; Kim E; Shin JK; Lee Y
    Arch Pharm Res; 1999 Apr; 22(2):202-7. PubMed ID: 10230513
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aryl sulfonamides as selective PDE4 inhibitors.
    Montana JG; Buckley GM; Cooper N; Dyke HJ; Gowers L; Gregory JP; Hellewell PG; Kendall HJ; Lowe C; Maxey R; Miotla J; Naylor RJ; Runcie KA; Tuladhar B; Warneck JB
    Bioorg Med Chem Lett; 1998 Oct; 8(19):2635-40. PubMed ID: 9873594
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma.
    Christensen SB; Guider A; Forster CJ; Gleason JG; Bender PE; Karpinski JM; DeWolf WE; Barnette MS; Underwood DC; Griswold DE; Cieslinski LB; Burman M; Bochnowicz S; Osborn RR; Manning CD; Grous M; Hillegas LM; Bartus JO; Ryan MD; Eggleston DS; Haltiwanger RC; Torphy TJ
    J Med Chem; 1998 Mar; 41(6):821-35. PubMed ID: 9526558
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pulmonary antiallergic and antiinflammatory effects of a novel, orally-active phosphodiesterase IV inhibitor (WAY-127093B) in guinea pigs and rats.
    Howell RE; Woeppel SL; Howell DE; Rubin EB; Jenkins LP; Golankiewicz JM; Lombardo LJ; Heaslip RJ
    Inflamm Res; 1995 Aug; 44 Suppl 2():S172-3. PubMed ID: 8548383
    [No Abstract]   [Full Text] [Related]  

  • 32. 2-Substituted-4-methoxybenzimidazole-based PDE4 inhibitors.
    Regan J; Bruno J; McGarry D; Poli G; Hanney B; Bower S; Travis J; Sweeney D; Miller B; Souness J; Djuric S
    Bioorg Med Chem Lett; 1998 Oct; 8(19):2737-42. PubMed ID: 9873613
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hunting the emesis and efficacy targets of PDE4 inhibitors: identification of the photoaffinity probe 8-(3-azidophenyl)-6- [(4-iodo-1H-1-imidazolyl)methyl]quinoline (APIIMQ).
    Macdonald D; Perrier H; Liu S; Laliberté F; Rasori R; Robichaud A; Masson P; Huang Z
    J Med Chem; 2000 Oct; 43(21):3820-3. PubMed ID: 11052785
    [No Abstract]   [Full Text] [Related]  

  • 34. The synthesis and biological evaluation of a novel series of phthalazine PDE4 inhibitors I.
    Napoletano M; Norcini G; Pellacini F; Marchini F; Morazzoni G; Ferlenga P; Pradella L
    Bioorg Med Chem Lett; 2000 Oct; 10(19):2235-8. PubMed ID: 11012037
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Studies on mechanisms of low emetogenicity of YM976, a novel phosphodiesterase type 4 inhibitor.
    Aoki M; Fukunaga M; Sugimoto T; Hirano Y; Kobayashi M; Honda K; Yamada T
    J Pharmacol Exp Ther; 2001 Sep; 298(3):1142-9. PubMed ID: 11504812
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNF alpha inhibitory activity of two series of rolipram analogues: implications for a new active site model of PDE4.
    Kleinman EF; Campbell E; Giordano LA; Cohan VL; Jenkinson TH; Cheng JB; Shirley JT; Pettipher ER; Salter ED; Hibbs TA; DiCapua FM; Bordner J
    J Med Chem; 1998 Jan; 41(3):266-70. PubMed ID: 9464356
    [No Abstract]   [Full Text] [Related]  

  • 37. Highly potent PDE4 inhibitors with therapeutic potential.
    Ochiai H; Ohtani T; Ishida A; Kusumi K; Kato M; Kohno H; Odagaki Y; Kishikawa K; Yamamoto S; Takeda H; Obata T; Nakai H; Toda M
    Bioorg Med Chem; 2004 Sep; 12(17):4645-65. PubMed ID: 15358291
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis and profile of SCH351591, a novel PDE4 inhibitor.
    Billah M; Cooper N; Cuss F; Davenport RJ; Dyke HJ; Egan R; Ganguly A; Gowers L; Hannah DR; Haughan AF; Kendall HJ; Lowe C; Minnicozzi M; Montana JG; Naylor R; Oxford J; Peake JC; Piwinski JJ; Runcie KA; Sabin V; Sharpe A; Shih NY; Warneck JB
    Bioorg Med Chem Lett; 2002 Jun; 12(12):1621-3. PubMed ID: 12039576
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thalidomide analogs and PDE4 inhibition.
    Muller GW; Shire MG; Wong LM; Corral LG; Patterson RT; Chen Y; Stirling DI
    Bioorg Med Chem Lett; 1998 Oct; 8(19):2669-74. PubMed ID: 9873600
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and evaluation of a novel series of phosphodiesterase IV inhibitors. A potential treatment for asthma.
    Beasley SC; Cooper N; Gowers L; Gregory JP; Haughan AF; Hellewell PG; Macari D; Miotla J; Montana JG; Morgan T; Naylor R; Runcie KA; Tuladhar B; Warneck JB
    Bioorg Med Chem Lett; 1998 Oct; 8(19):2629-34. PubMed ID: 9873593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.